Quotes

Company Overview

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company’s product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

CEO： Chacko M.B.A., M.D., Jacob M.

Market： NASDAQ

Hot List

TradeSearchNews

SymbolLatest price%Chg

Moomoo > Quotes > ORIC Oric Pharmaceuticals > Detailed Quotes

ORIC Oric Pharmaceuticals

3.480-0.200-5.43%

Trading Session 05/19 13:56 ET

High

3.690

Open

3.600

Turnover

460.93K

Low

3.400

Pre Close

3.680

Volume

131.59K

Intraday

Price Forecast

No Data

ORIC Oric Pharmaceuticals

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other